GoAI
Get started
Inventiva S.A. logo

Inventiva S.A.

IVA

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

€4.68

+€0.03 · +0.65%

Aug 21, 4:00 PM ET

IVA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

11

Overpriced

Momentum

31

Weakening

Sentiment

44

Mixed

Risk resilience

34

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.

Industry
Biotechnology
Sector
Healthcare
Headquarters
FR
CEO
Andrew Obenshain
Listed since
Jul 10, 2020
Employees
73

Market position

Day range

Current €4.68

52-week range

Current €4.68

Open
€4.63
Previous close
€4.65
Volume
461.4K
0.58× average
Average volume
802.33K
Average daily volume
Market cap
243.28M EUR
Beta
0.91
Market reference 1
50-day average
€4.2715
+9.56% above average
200-day average
€5.0324
-7.00% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
828.76M EUR
P/E (TTM)
-2.12×
P/B (TTM)
-89.79×
P/S (TTM)
211.82×
EV / EBITDA
-6.47×
Earnings yield
-39.16%
Free cash flow yield
-11.65%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
35.07%
Operating margin
-3037.30%
Net margin
-7899.58%
Return on equity
1171.53%
Return on assets
-136.68%
Return on invested capital
-64.24%

Financial health

Debt / equity
-2.1×
Current ratio
3.15×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends913%-2178%-5269%-8361%Gross margin, FY2021: 100.00%Gross margin, FY2022: 140.05%Gross margin, FY2023: 100.13%Gross margin, FY2024: 100.00%Gross margin, FY2025: 33.68%Operating margin, FY2021: -1242.58%Operating margin, FY2022: -468.92%Operating margin, FY2023: -587.68%Operating margin, FY2024: -1060.64%Operating margin, FY2025: -2920.96%Net margin, FY2021: -1183.50%Net margin, FY2022: -445.64%Net margin, FY2023: -631.84%Net margin, FY2024: -2002.74%Net margin, FY2025: -7587.80%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 140.05%. Gross margin FY2023 100.13%. Gross margin FY2024 100.00%. Gross margin FY2025 33.68%. Operating margin FY2021 -1242.58%. Operating margin FY2022 -468.92%. Operating margin FY2023 -587.68%. Operating margin FY2024 -1060.64%. Operating margin FY2025 -2920.96%. Net margin FY2021 -1183.50%. Net margin FY2022 -445.64%. Net margin FY2023 -631.84%. Net margin FY2024 -2002.74%. Net margin FY2025 -7587.80%.

Income trends

Revenue

4.48M EUR-51.26%

Operating income

−130.95M EUR-34.22%

Net income

−340.16M EUR-84.66%
Income trends across reported periods53.24M EUR−89.81M EUR−232.87M EUR−375.92M EURRevenue, FY2021: 4.19M EURRevenue, FY2022: 12.18M EURRevenue, FY2023: 17.48M EURRevenue, FY2024: 9.2M EURRevenue, FY2025: 4.48M EUROperating income, FY2021: −52.11M EUROperating income, FY2022: −57.11M EUROperating income, FY2023: −102.71M EUROperating income, FY2024: −97.56M EUROperating income, FY2025: −130.95M EURNet income, FY2021: −49.64M EURNet income, FY2022: −54.27M EURNet income, FY2023: −110.43M EURNet income, FY2024: −184.21M EURNet income, FY2025: −340.16M EURFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 4.19M EUR. Revenue FY2022 12.18M EUR. Revenue FY2023 17.48M EUR. Revenue FY2024 9.2M EUR. Revenue FY2025 4.48M EUR. Operating income FY2021 −52.11M EUR. Operating income FY2022 −57.11M EUR. Operating income FY2023 −102.71M EUR. Operating income FY2024 −97.56M EUR. Operating income FY2025 −130.95M EUR. Net income FY2021 −49.64M EUR. Net income FY2022 −54.27M EUR. Net income FY2023 −110.43M EUR. Net income FY2024 −184.21M EUR. Net income FY2025 −340.16M EUR.
Metric (EUR)FY2025FY2024FY2023FY2022FY2021
Revenue4.48M EUR9.2M EUR17.48M EUR12.18M EUR4.19M EUR
Cost of goods sold2.8M EUR3.88M EUR−23K EUR995K EUR1.02M EUR
Gross profit1.51M EUR9.2M EUR17.5M EUR17.06M EUR4.19M EUR
Research and development83.61M EUR90.88M EUR110.01M EUR60.47M EUR48.45M EUR
Selling, general, and administrative53.89M EUR17.1M EUR15.61M EUR15.5M EUR11.52M EUR
Operating expenses137.37M EUR106.76M EUR120.19M EUR74.17M EUR56.31M EUR
Interest income2.83M EUR1.14M EUR945K EUR390K EUR57K EUR
Interest expense32.3M EUR12.18M EUR5.18M EUR707K EUR138K EUR
Depreciation and amortization2.8M EUR5.2M EUR2.6M EUR870K EUR858K EUR
Operating income−130.95M EUR−97.56M EUR−102.71M EUR−57.11M EUR−52.11M EUR
Net income−340.16M EUR−184.21M EUR−110.43M EUR−54.27M EUR−49.64M EUR

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
36%
4 beats, 7 misses, 0 met estimates
Average EPS surprise
-123.48%
11 comparable reports
Latest EPS result
-1.07
Estimate -0.23 · Miss by 365.22%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.2-0.91-1.63-2.35Q1 '23MissQ3 '23MissQ1 '24MissQ3 '24MissQ1 '25MissQ3 '25MissQ1 '26MissQ3 '26Estimate
Q1 2023, reported Mar 29, 2023: actual -0.636, estimate -0.568, surprise -11.90%, Miss. Q3 2023, reported Sep 28, 2023: actual -1.43, estimate -1.27, surprise -13.09%, Miss. Q1 2024, reported Mar 27, 2024: actual -1.25, estimate -0.4, surprise -211.66%, Miss. Q3 2024, reported Sep 25, 2024: actual -1.01, estimate -0.56, surprise -81.10%, Miss. Q1 2025, reported Mar 26, 2025: actual -2.19, estimate -0.44, surprise -398.10%, Miss. Q3 2025, reported Sep 25, 2025: actual -1.89, estimate -0.41, surprise -361.73%, Miss. Q1 2026, reported Mar 30, 2026: actual -1.07, estimate -0.23, surprise -365.22%, Miss. Q3 2026, reported Sep 25, 2026: actual —, estimate -0.423, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates19.54M13.42M7.3M1.18MQ1 '23BeatQ3 '23BeatQ1 '24BeatQ3 '24No estimateQ1 '25BeatQ3 '25MissQ1 '26MissQ3 '26Estimate
Q1 2023, reported Mar 29, 2023: actual 16.61M EUR, estimate 15.7M EUR, surprise +5.80%, Beat. Q3 2023, reported Sep 28, 2023: actual 7.22M EUR, estimate 1.39M EUR, surprise +419.32%, Beat. Q1 2024, reported Mar 27, 2024: actual 18.19M EUR, estimate 15.3M EUR, surprise +18.93%, Beat. Q3 2024, reported Sep 25, 2024: actual 2.94M EUR, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 26, 2025: actual 10.96M EUR, estimate 6.4M EUR, surprise +71.24%, Beat. Q3 2025, reported Sep 25, 2025: actual 5.22M EUR, estimate 8.67M EUR, surprise -39.84%, Miss. Q1 2026, reported Mar 30, 2026: actual 2.3M EUR, estimate 5.15M EUR, surprise -55.34%, Miss. Q3 2026, reported Sep 25, 2026: actual —, estimate 4.76M EUR, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

€15.33

227.56% upside
Past 12 months12-month forecastHigh €24.00Average €15.33Low €12.00

IVA news

seekingalpha.com

Inventiva: MASH Is Becoming A Combination Market Before Lanifibranor Arrives

Inventiva is positioned as a high-risk, clinical catalyst play targeting MASH with its oral pan-PPAR agonist, lanifibranor. Lanifibranor's potential lies in combination therapy, offering dual metabolic and anti-fibrotic…

Read source
globenewswire.com

Correction: Inventiva Announces Preliminary Financial Results for the First Half of 2026¹

Daix (France), New York City (New York, United States), July 30, 2026 – Update to Press Release Dated July 29, 2026. The Company wishes to correct an error in the press release issued on July 29, 2026. On page 2, the…

Read source
globenewswire.com

Inventiva Announces Preliminary Financial Results for the First Half of 2026¹

Daix (France), New York City (New York, United States), July 29, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of…

Read source
defenseworld.net

ADAR1 Capital Management LLC Sells 535,448 Shares of Inventiva S.A. Sponsored ADR $IVA

ADAR1 Capital Management LLC decreased its holdings in shares of Inventiva S.A. Sponsored ADR (NASDAQ: IVA) by 19.8% in the undefined quarter, according to the company in its most recent disclosure with the Securities…

Read source
globenewswire.com

Inventiva Announces Completion of the EIB Warrant Restructuring with the Issuance of New EIB Warrants

Daix (France), New York City (New York, United States), July 9, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of…

Read source
globenewswire.com

Results of the Votes of the Combined Shareholders' General Meeting of June 30, 2026

Daix (France), New York City (New York, United States), July 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of…

Read source

IVA peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding IVA

Funds reporting this stock among their holdings, ordered by reported position size.

Simplify Propel Opportunities ETF logoSimplify Propel Opportunities ETFSURI
Market value
1.47M
Weight
1.73%
AUM
85.05M USD
Expense ratio
2.82%
Price / 1D
$19.8186-0.20%
Harbor Health Care ETF (MEDI) logoHarbor Health Care ETF (MEDI)MEDI
Market value
158.08K
Weight
0.36%
AUM
44.61M USD
Expense ratio
0.80%
Price / 1D
$34.98+0.69%
ActivePassive International Equity ETF logoActivePassive International Equity ETFAPIE
Market value
47.1K
Weight
—
AUM
953.79M USD
Expense ratio
0.45%
Price / 1D
$39.766+1.16%
State Street SPDR Portfolio Europe ETF logoState Street SPDR Portfolio Europe ETFSPEU
Market value
36.61K
Weight
0.00%
AUM
741.65M USD
Expense ratio
0.07%
Price / 1D
$57.325+0.75%

Continue in GoAI

Research IVA

research.disclaimer